ANNEXON, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
ANNEXON, INC. (ANNX) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $6.30 million for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-11-16.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2020-11-16
- ANNEXON, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-06-30 was $6.30M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month |
|---|---|
| 2020-06-30 | $6.30M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |